ARID2: a new tumor suppressor gene in hepatocellular carcinoma - PubMed
Review
doi: 10.18632/oncotarget.355.
Jian Wang, Yongqing Han, Zhen Huang, Jianming Ying, Xinyu Bi, Jianjun Zhao, Yi Fang, Haitao Zhou, Jianguo Zhou, Zhiyu Li, Yefan Zhang, Xue Yang, Tao Yan, Linfang Wang, Michael S Torbenson, Jianqiang Cai
Affiliations
- PMID: 22095441
- PMCID: PMC3259997
- DOI: 10.18632/oncotarget.355
Review
ARID2: a new tumor suppressor gene in hepatocellular carcinoma
Hong Zhao et al. Oncotarget. 2011 Nov.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, however, genetic-environmental interactions and mechanisms associated with the development of HCC remains largely unclear. Our recent work described novel inactivating mutations of ARID2 (AT-rich interactive domain 2) in four major subtypes of HCC through exomic sequencing of ten HCV-associated HCCs and subsequent evaluation of the tumors from additional affected individuals. Here, we summarize the current knowledge about the relevance of ARID2 in HCC and the implication in future patient care.
Figures

a, Somatic alterations identified in the ARID2 gene. *, nonsense mutations; #, frame-shifting indels; &, splice site mutation. b, ARID2 protein and the inactivating alterations (red arrows) Truncating mutations are indicated by red arrows. ARID, AT-rich interaction domain; RFX, RFX-like DNA binding motif; GLN, Proline-and glutamine-rich region; ZnF, C2H2 Zinc Fingers.

IFN, Interferon; IFNAR, Interferon-α/β/γ receptor; PBAF, Polybromo-associated BRG1-associated factor; ISRE, Interferon-sensitive response element; GAS, Interferon-γ-activated site; STAT1, Signal transducers and activators of transcription 1.
Similar articles
-
ARID2 Chromatin Remodeler in Hepatocellular Carcinoma.
Loesch R, Chenane L, Colnot S. Loesch R, et al. Cells. 2020 Sep 23;9(10):2152. doi: 10.3390/cells9102152. Cells. 2020. PMID: 32977645 Free PMC article. Review.
-
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma.
Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, Pawlik TM, Daniel HD, Kannangai R, Offerhaus GJ, Velculescu VE, Wang L, Zhou S, Vogelstein B, Hruban RH, Papadopoulos N, Cai J, Torbenson MS, Kinzler KW. Li M, et al. Nat Genet. 2011 Aug 7;43(9):828-9. doi: 10.1038/ng.903. Nat Genet. 2011. PMID: 21822264 Free PMC article.
-
ARID2 modulates DNA damage response in human hepatocellular carcinoma cells.
Oba A, Shimada S, Akiyama Y, Nishikawaji T, Mogushi K, Ito H, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Asahara H, Kaida A, Miura M, Tanabe M, Tanaka S. Oba A, et al. J Hepatol. 2017 May;66(5):942-951. doi: 10.1016/j.jhep.2016.12.026. Epub 2017 Feb 24. J Hepatol. 2017. PMID: 28238438
-
Jiang H, Cao HJ, Ma N, Bao WD, Wang JJ, Chen TW, Zhang EB, Yuan YM, Ni QZ, Zhang FK, Ding XF, Zheng QW, Wang YK, Zhu M, Wang X, Feng J, Zhang XL, Cheng SQ, Ma DJ, Qiu L, Li JJ, Xie D. Jiang H, et al. Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4770-4780. doi: 10.1073/pnas.1914937117. Epub 2020 Feb 18. Proc Natl Acad Sci U S A. 2020. PMID: 32071245 Free PMC article.
-
Genetic aspects of hepatocellular carcinogenesis.
Ozturk M. Ozturk M. Semin Liver Dis. 1999;19(3):235-42. doi: 10.1055/s-2007-1007113. Semin Liver Dis. 1999. PMID: 10518303 Review.
Cited by
-
ARID2 Chromatin Remodeler in Hepatocellular Carcinoma.
Loesch R, Chenane L, Colnot S. Loesch R, et al. Cells. 2020 Sep 23;9(10):2152. doi: 10.3390/cells9102152. Cells. 2020. PMID: 32977645 Free PMC article. Review.
-
Ji X, Zhang Q, Du Y, Liu W, Li Z, Hou X, Cao G. Ji X, et al. Curr Genomics. 2014 Dec;15(6):469-80. doi: 10.2174/1389202915666141114213833. Curr Genomics. 2014. PMID: 25646075 Free PMC article.
-
Zhang Y, Song J, Rutenberg D, Sokol L. Zhang Y, et al. Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020007. doi: 10.4084/MJHID.2020.007. eCollection 2020. Mediterr J Hematol Infect Dis. 2020. PMID: 31934317 Free PMC article.
-
Trejo-Villegas OA, Heijink IH, Ávila-Moreno F. Trejo-Villegas OA, et al. Mol Ther. 2024 Aug 7;32(8):2470-2488. doi: 10.1016/j.ymthe.2024.06.026. Epub 2024 Jun 22. Mol Ther. 2024. PMID: 38910326 Review.
-
CREB1 acts via the miR‑922/ARID2 axis to enhance malignant behavior of liver cancer cells.
Liu X, Zhang H, Zhou P, Yu Y, Zhang H, Chen L, Gong J, Liu Z. Liu X, et al. Oncol Rep. 2021 May;45(5):79. doi: 10.3892/or.2021.8030. Epub 2021 Mar 31. Oncol Rep. 2021. PMID: 33786634 Free PMC article.
References
-
- El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76. - PubMed
-
- Society AC. Cancer Facts and Figures. 2009
-
- Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674–87. - PubMed
-
- Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology. 2002;181-182:43–7. - PubMed
-
- Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004;127:S72–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical